Medicare Enrolled
Dr. Amanullah Khan, MD, PHD
Hematology & Oncology · Mckinney, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Khan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Khan?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Khan
Dr. Amanullah Khan is a hematology & oncology specialist in Mckinney, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Khan performed 6,367 Medicare services across 1,201 unique beneficiaries.
Between the years covered by Open Payments, Dr. Khan received a total of $2,272 from 38 pharmaceutical and/or device companies across 144 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Khan is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 39% volume in TX
$2,272 industry payments
Medicare Practice Summary
Medicare Utilization ↗6,367
Medicare services
Top 39% in TX for hematology & oncology
1,201
Unique beneficiaries
$32
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~318 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 1,800 | $18 | $43 |
| Flow cytometry, additional marker An additional marker is tested during a flow cytometry procedure to analyze DNA or cells. This step adds specific data points to the initial analysis. |
915 | $18 | $47 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
727 | $8 | $12 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
527 | $82 | $319 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
463 | $3 | $3 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
434 | $1 | $1 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
225 | $21 | $90 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
165 | $10 | $42 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
144 | $46 | $205 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
122 | $11 | $47 |
| Injection, triptorelin pamoate, 3.75 mg | 102 | $287 | $1,500 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
92 | $1 | $10 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
86 | $0 | $2 |
| Methylprednisolone injection, up to 40 mg An injection of methylprednisolone sodium succinate, a corticosteroid medication, administered in a dose of up to 40 mg. |
75 | $3 | $6 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
73 | $16 | $63 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
72 | $21 | $92 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
71 | $89 | $404 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
49 | $0 | $1 |
| Flow cytometry DNA or cell analysis, first marker A laboratory test that uses a laser to analyze cells or DNA by detecting a specific marker on the cell surface or within the cell. |
35 | $51 | $127 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
32 | $57 | $518 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
30 | $116 | $285 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 29 | $116 | $450 |
| CT scan of chest, without contrast A computed tomography scan of the chest area that uses X-rays to create detailed images without the use of contrast dye. |
27 | $62 | $318 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
27 | $1,197 | $7,881 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
23 | $181 | $1,084 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
22 | $59 | $145 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
14.9% high complexity
40.6% medium
44.5% routine
Industry Payment Transparency
Open Payments through 2023 ↗$2,272
Total received (2018-2023)
Avg $379/year across 6 years
Bottom 42% in TX for hematology & oncology
38
Companies
144
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,246 (98.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$26 (1.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2023
$94
2022
$285
2021
$326
2020
$355
2019
$572
2018
$642
Payments by company (2023)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$369
Merck Sharp & Dohme Corporation
$174
Tactile Systems Technology Inc
$156
PFIZER INC.
$141
Celgene Corporation
$130
Astellas Pharma US Inc
$98
Novartis Pharmaceuticals Corporation
$92
Agios Pharmaceuticals, Inc.
$72
Incyte Corporation
$63
Boehringer Ingelheim Pharmaceuticals, Inc.
$63
Genentech USA, Inc.
$61
Regeneron Healthcare Solutions, Inc.
$58
Rigel Pharmaceuticals, Inc.
$58
GENZYME CORPORATION
$47
PUMA BIOTECHNOLOGY, INC.
$43
Janssen Biotech, Inc.
$42
Bayer HealthCare Pharmaceuticals Inc.
$39
Clovis Oncology, Inc.
$39
Puma Biotechnology, Inc.
$38
Gilead Sciences, Inc.
$37
Blue Earth Diagnostics Limited
$37
AstraZeneca Pharmaceuticals LP
$36
Lilly USA, LLC
$35
Amgen Inc.
$35
Medtronic USA, Inc.
$32
Epizyme, Inc.,
$31
Pharmacyclics LLC, an AbbVie Company
$27
Medtronic, Inc.
$26
Daiichi Sankyo Inc.
$26
AbbVie, Inc.
$24
Janssen Pharmaceuticals, Inc
$22
Myriad Genetic Laboratories, Inc.
$22
Dova Pharmaceuticals
$21
Karyopharm Therapeutics Inc.
$19
Mylan Institutional Inc.
$17
Blueprint Medicines Corporation
$15
Dendreon Pharmaceuticals LLC
$15
Teva Pharmaceuticals USA, Inc.
$15
Top 3 companies account for 30.7% of total payments
Associated products mentioned in payments ›
ABECMA · AFINITOR · ALIMTA · AYVAKIT · Axumin · BENDEKA · COSELA · CYRAMZA · DARZALEX · Doptelet · EMEND · Enhertu · Erleada · FLEXITOUCH · Flexitouch Plus · GILOTRIF · Herceptin · IBRANCE · IDHIFA · IMBRUVICA · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · LEXISCAN · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LUMAKRAS · LYNPARZA · MEKINIST · NERLYNX · Neulasta · Nexavar · Nubeqa · OPDIVO · OSTEOCOOL RF ABLATION · OSTEOCOOL RF ABLATION SYSTEM · Ogivri · PADCEV · PROVENGE · Perjeta · Pomalyst · PreciseTumor · Revlimid · Rubraca · TASIGNA · TAZVERIK · TECENTRIQ · TIBSOVO · Tavalisse · Trodelvy · Venclexta · XALKORI · XARELTO · XPOVIO · XTANDI · Xtandi · YERVOY
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $36 per 100 Medicare services performed
Geographic Context
Hematology & oncology specialists within 10 mi
43
Per 100K population
3.9
County median income
$117,588
Nearest hospital
MEDICAL CENTER OF MCKINNEY
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2023 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Khan is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Khan experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Khan performed 1,800 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Khan receive payments from pharmaceutical companies?
Yes. Dr. Khan received a total of $2,272 from 38 companies across 144 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Khan's costs compare to other hematology & oncology specialists in Mckinney?
Dr. Khan's average Medicare payment per service is $32. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Khan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Mckinney
Browse hematology & oncology specialists in Mckinney ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
By company
Tactile Systems Technology Inc Payments to Doctors
See all physicians who received payments from Tactile Systems Technology Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology